Journal of Cancer Research and Therapeutics · 2016 · 36 citations · 6 references
MedicineOncologySurgeryCancer ControlOncologic SurgerySurgical OncologyAblation TherapyHepatobiliary CancerHepatobiliary SurgeryHepatocellular CarcinomaInterventional OncologyLiver CancerAblation Of Liver TumorsControl Group DesignHepatocellular Carcinoma TreatmentLiver Tumor AblationMatched Control GroupOncologic Outcomes Of AblationPercutaneous AblationSurvival Rates
OBJECTIVE: To evaluate the safety and efficacy of transcatheter arterial chemoembolization (TACE) combined with percutaneous microwave ablation (MWA) in the treatment of advanced hepatocellular carcinoma (HCC). MATERIALS AND METHODS: Three thousand cases of advanced HCC patients were randomly divided into two groups: 1500 cases in the treatment group were treated with TACE combined with MWA and 1500 cases in the control group were treated with TACE. RESULTS: The effective rate of the treatment group and control group was 71.4% and 42.8%, respectively, and the difference between the two groups was statistically significant (P < 0.05). During the follow-up period at 6, 12, 18, and 24 months postoperatively, the survival rates of the treatment group were 88.1%, 73.8%, 52.3%, and 33.3%, and the survival rates of the control group were 76.2%, 57.1%, 30.9%, and 9.5%, respectively. There was no significant difference in postoperative complications between the two groups. CONCLUSION: It is safe and effective to use TACE combined with MWA in the treatment of advanced HCC, and the effect of combined treatment is better than that of TACE alone.
6
Xin Yin, Lan Zhang, Yanhong Wang et al. · BMC Cancer · 2014 · 115 citations · Full text
L. Xu, Hongliang Sun, Yao‐Ting Chen et al. · Journal of Gastroenterology and Hepatology · 2012 · 76 citations